A Phase II trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcomas Wilms Tumor Hepatocellular Carcinoma and Papillary Thyroid Carcinoma
Study on Investigational Treatment for Migraine Relief
Not Recruiting
2 years - 30 years
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Who can participate: Adults aged 18-65 who experience chronic migraines and meet specific health criteria are eligible to participate.
Study details: Participants will receive either the investigational treatment or a placebo during the study. They will be required to attend regular clinic visits for health assessments and to track their migraine symptoms.
Updated on
19 Feb 2024.
Study ID: 1201007776
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
